PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 16621886-4 2006 Our western blot analysis showed that berberine-induced G(1) cell cycle arrest was mediated through the increased expression of Cdki proteins (Cip1/p21 and Kip1/p27), a simultaneous decrease in Cdk2, Cdk4, Cdk6 and cyclins D1, D2 and E and enhanced binding of Cdki-Cdk. Berberine 38-47 cyclin D1 Homo sapiens 215-235 18430372-0 2008 Berberine inhibits cyclin D1 expression via suppressed binding of AP-1 transcription factors to CCND1 AP-1 motif. Berberine 0-9 cyclin D1 Homo sapiens 19-28 18430372-0 2008 Berberine inhibits cyclin D1 expression via suppressed binding of AP-1 transcription factors to CCND1 AP-1 motif. Berberine 0-9 cyclin D1 Homo sapiens 96-101 18430372-10 2008 Berberine could inhibit the expression of cyclin D1 in PG cells. Berberine 0-9 cyclin D1 Homo sapiens 42-51 18430372-12 2008 Berberine suppressed the expression of c-Jun and decreased the binding of transcription factors to the CCND1 AP-1 motif. Berberine 0-9 cyclin D1 Homo sapiens 103-108 18430372-13 2008 CONCLUSION: Berberine suppresses the activity of the AP-1 signaling pathway and decreases the binding of transcription factors to the CCND1 AP-1 motif. Berberine 12-21 cyclin D1 Homo sapiens 134-139 18430372-14 2008 This is one of the important mechanisms behind the antitumoral effects of berberine as a regulator of cyclin D1. Berberine 74-83 cyclin D1 Homo sapiens 102-111 19189664-5 2008 Berberine much greatly decreased G0/G1 phase-associated cyclin and cyclin-dependent kinase (cyclin D1, cyclin E, Cdk2, and Cdk4) expression, and increased apoptotic gene expression and activation of caspase-3 in SK-N-SH cells. Berberine 0-9 cyclin D1 Homo sapiens 92-101 18593939-8 2008 Berberine also suppressed the expression of NF-kappaB-regulated gene products involved in antiapoptosis (Bcl-xL, Survivin, IAP1, IAP2, and cFLIP), proliferation (cyclin D1), inflammation (cyclooxygenase-2), and invasion (matrix metalloproteinase-9). Berberine 0-9 cyclin D1 Homo sapiens 162-171 33450878-6 2021 Further analyses exhibited that berberine treatment caused G0/G1 phase arrest at 48 h due to high cyclin D1 (CCND1) and low cyclin-dependent kinase 4 (CDK4) protein and mRNA levels, simultaneous downregulation of human telomerase reverse transcriptase (TERT) mRNA and human telomerase RNA component (TERC) levels, as well as a decrease in the TERT protein level and telomerase activity. Berberine 32-41 cyclin D1 Homo sapiens 98-107 34981469-9 2021 The expression levels of all tested genes were altered in all treatment groups compared to the control, with that of WNT1, CTNNB1, TCF, MTOR, AKT1, BIRC5, and CCND1 showing the most robust changes in the combined curcumin/berberine/5-FU treatment. Berberine 222-231 cyclin D1 Homo sapiens 159-164 33325633-5 2021 Furthermore, berberine suppressed the activation of the EGFR and ErbB2 downstream targets cyclin D1, MMPs, and VEGF by down-regulating the EGFR-ErbB2/PI3K/Akt signaling pathway. Berberine 13-22 cyclin D1 Homo sapiens 90-99 33450878-6 2021 Further analyses exhibited that berberine treatment caused G0/G1 phase arrest at 48 h due to high cyclin D1 (CCND1) and low cyclin-dependent kinase 4 (CDK4) protein and mRNA levels, simultaneous downregulation of human telomerase reverse transcriptase (TERT) mRNA and human telomerase RNA component (TERC) levels, as well as a decrease in the TERT protein level and telomerase activity. Berberine 32-41 cyclin D1 Homo sapiens 109-114 33262612-13 2020 Berberine also reduced mutp53 content and caused G2 phase arrest in U251 cells with a concurrent decrease in p21, cyclin D1, and cyclin B1 content. Berberine 0-9 cyclin D1 Homo sapiens 114-123 24015932-6 2013 In clinical practice, oral administration of berberine also significantly reduced the familial adenomatous polyposis patients" polyp size along with the inhibition of cyclin D1 expression in polyp samples. Berberine 45-54 cyclin D1 Homo sapiens 167-176 32915362-11 2020 The increase in berberine concentration led to an increase in miRNA-582-5p and miRNA-188-5p expression and a decrease in the expression of mRNA for the corresponding target genes encoding CDK1, CDK2, and cyclins D1 and A. Berberine 16-25 cyclin D1 Homo sapiens 204-220 30911957-6 2019 Berberine decreased the expression of protein levels of cyclin D1, cyclin E, CDK2, CDK4, and CDK6 to cause G1 phase arrest. Berberine 0-9 cyclin D1 Homo sapiens 56-65 29061795-7 2017 RESULTS: Compared to berberine or evodiamine treatments alone, the combination treatment of berberine (25 muM) and evodiamine (15 muM) synergistically inhibited the proliferation of MCF-7 cells in a time-dependent manner and resulted in the G0/G1 phase accumulation of cells that exhibited increased expression levels of the CDK inhibitors p21 and p27 with a concomitant reduction in the expression levels of cell-cycle checkpoint proteins cyclin D1, cyclin E, CDK4, and CDK6. Berberine 92-101 cyclin D1 Homo sapiens 440-449 28566619-7 2017 The inhibition was largely attributed to cell cycle arrest at the G1 phase through the reduction of cyclin D1, and cyclin E. Moreover, berberine could reduce the expression and activation of signal transducers and activator of transcription 3 (STAT3) and probably nuclear factor-kappaB (NF-kappaB) via suppression of extracellular signal-regulated kinase (ERK) 1/2 action. Berberine 135-144 cyclin D1 Homo sapiens 100-109 27854312-0 2016 Berberine Suppresses Cyclin D1 Expression through Proteasomal Degradation in Human Hepatoma Cells. Berberine 0-9 cyclin D1 Homo sapiens 21-30 27854312-1 2016 The aim of this study is to explore the underlying mechanism on berberine-induced Cyclin D1 degradation in human hepatic carcinoma. Berberine 64-73 cyclin D1 Homo sapiens 82-91 27854312-2 2016 We observed that berberine could suppress both in vitro and in vivo expression of Cyclin D1 in hepatoma cells. Berberine 17-26 cyclin D1 Homo sapiens 82-91 27854312-3 2016 Berberine exhibits dose- and time-dependent inhibition on Cyclin D1 expression in human hepatoma cell HepG2. Berberine 0-9 cyclin D1 Homo sapiens 58-67 27854312-4 2016 Berberine increases the phosphorylation of Cyclin D1 at Thr286 site and potentiates Cyclin D1 nuclear export to cytoplasm for proteasomal degradation. Berberine 0-9 cyclin D1 Homo sapiens 43-52 27854312-4 2016 Berberine increases the phosphorylation of Cyclin D1 at Thr286 site and potentiates Cyclin D1 nuclear export to cytoplasm for proteasomal degradation. Berberine 0-9 cyclin D1 Homo sapiens 84-93 27854312-5 2016 In addition, berberine recruits the Skp, Cullin, F-box containing complex-beta-Transducin Repeat Containing Protein (SCFbeta-TrCP) complex to facilitate Cyclin D1 ubiquitin-proteasome dependent proteolysis. Berberine 13-22 cyclin D1 Homo sapiens 153-162 27854312-6 2016 Knockdown of beta-TrCP blocks Cyclin D1 turnover induced by berberine; blocking the protein degradation induced by berberine in HepG2 cells increases tumor cell resistance to berberine. Berberine 60-69 cyclin D1 Homo sapiens 30-39 27738318-8 2016 The expressions of Bcl-xL and Cyclind1 proteins were decreased, whereas the levels of cleavage of poly-ADP ribose polymerase (PARP) were considerably increased in the cell lines in response to berberine treatment. Berberine 193-202 cyclin D1 Homo sapiens 30-38 27904693-5 2016 Berberine also downregulated the expression of SP1, CCND1, and BCL2, determined with western blotting. Berberine 0-9 cyclin D1 Homo sapiens 52-57 27904693-8 2016 Therefore, we conclude that berberine treatment suppresses cancer cell growth by regulating miR-22-3p and SP1 and its downstream targets, CCND1 and BCL2, in HCC. Berberine 28-37 cyclin D1 Homo sapiens 138-143 19909759-9 2010 Furthermore, berberine and the extract inhibited the expression of the proto-oncogene cyclin D1. Berberine 13-22 cyclin D1 Homo sapiens 86-95